A Phase 2 interventional study of Moxifloxacin/dexamethasone phosphate ophthalmic solution and Moxifloxacin ophthalmic solution 0.5% in Corneal Infiltrates, sponsored by Alcon Research. Terminated at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-12-05.
Sponsored by Alcon Research (part of Alcon) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Corneal Diseases with a site in United States — 12 open to participants now, 13 under way, 3 of them phase 3. Corneal Diseases · United States.
Among the 76 studies in Corneal Diseases with a site in United States, this one is the 19th largest by enrollment of the 54 interventional ones that give a count, is one of 8 that started in 2007, is one of 6 in phase 2, and was the 17th registered.
219 studies on the registry are indexed under Corneal Diseases; 43 are open to participants now.
Browse Corneal Diseases studies →12 of the 76 studies in Corneal Diseases with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 20–79 · Healthy volunteers
University of Maryland, Baltimore · Sites in United States
Ages 18+ · Healthy volunteers
Woolfson Eye Institute · Sites in United States
Ages 8+
Duke University · Sites in United States
Ages 18+
Optos, PLC · Sites in United States
Ages 22+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Corneal Diseases studies recruiting now, 21 (64%) set no upper age limit and 5 (15%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 14 · Phase 4 5
First in 1992; this study’s year is marked. 8 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 144 is above the median of 40 across 132 interventional studies indexed under Corneal Diseases.
Median enrollment 79 across the 54 interventional studies, 90 across the 22 observational. Of the 54 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 76 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
Alcon has 2 studies filed under Corneal Diseases — fewer than ten, so there is no comparison to draw.
6 of the studies in Corneal Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06993597University of Maryland, BaltimoreStudy of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy | 2027-03 |
| NCT03030755The Cleveland ClinicCorneal Elastography and Patient Specific Modeling | 2027-05 |
| NCT06854393Henry M. Jackson Foundation for the Advancement of Military MedicineLacripep for Corneal Wound Healing Study | 2027-06 |
| NCT04439552Boston Children's HospitalfMRI and IVCM Cornea Microscopy of CXL in Keratoconus | 2027-08 |
| NCT07780890Massachusetts General HospitalA Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases | 2027-09-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 76 studies in Corneal Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine whether Moxidex ophthalmic solution is safe and effective in treating marginal corneal infiltrates.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Moxifloxacin/dexamethasone phosphate ophthalmic solution, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
Drug: Moxifloxacin/dexamethasone phosphate ophthalmic solution
Moxifloxacin ophthalmic solution 0.5%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
Drug: Moxifloxacin ophthalmic solution 0.5%
Dexamethasone phosphate solution, 0.1%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
Drug: Dexamethasone phosphate solution, 0.1%
Drug pages: Moxifloxacin · Dexamethasone phosphate
Also known as: Moxidex
Percentage of patients with resolution of all corneal stromal infiltrate(s) in study eye at Test of Cure (TOC) Visit (Day 10)
Time frame: Day 10
Percentage of patients with eradication of pre-therapy pathogens from the lid of the study eye at TOC Visit (Day 10)
Time frame: Day 10
The record gives a start of Dec 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Moxifloxacin · Dexamethasone phosphate